MGMT and glioblastoma: Based on these results, two randomized trials, CENTRIC and CORE, are currently ongoing to determine the efficacy of cilengitide for newly diagnosed glioblastoma with or without a methylated O6-methylguanine-DNA methyltransferase (MGMT) promoter [91, 92].